Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3Z activatory domain connected to 4-1BB costimulatory domain. Liso-cel, unlike the other two approved products—axicabtagene ciloleucel and tisagenlecleucel—is manufactured sepa...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Medknow Publications
2022-10-01
|
| シリーズ: | Hematology/Oncology and Stem Cell Therapy |
| 主題: | |
| オンライン･アクセス: | https://journals.lww.com/10.1016/j.hemonc.2021.09.004 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|